A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis

BACKGROUND: Treatment with nab-paclitaxel with gemcitabine demonstrates a survival advantage when compared with single-agent gemcitabine. However, the combination is associated with significant toxicities, leading to a high rate of drug discontinuation. We implemented a modified regimen of gemcitabi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Ahn, Daniel H., Krishna, Kavya, Blazer, Marlo, Reardon, Joshua, Wei, Lai, Wu, Christina, Ciombor, Kristen K., Noonan, Anne M., Mikhail, Sameh, Bekaii-Saab, Tanios
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5298402/
https://ncbi.nlm.nih.gov/pubmed/28203300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016676011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados